Introduction
Cancers of the female genital tract represent the third most common malignant neoplasms in women after cancers of the breast and of the digestive tract in Tunisia (Missaoui et al., 2010a) . The most common types of female genital tract cancers are cervical, ovarian and endometrial carcinoma. There are other less common tumors including tumors of vagina, vulva and fallopian tube. Neoplasms of the vulva and vagina account for less than 5% of all female genital tract cancers (Franco, 1996; Benedet et al., 2000; Wells et al., 2003) . Squamous cell carcinomas (SCCs) represent the most common malignant tumors, accounting for more than 85% in both localizations (Del Pino et al., 2013) . Vaginal and vulvar SCCs may have many of the same risk-factors as uterine cervix SCCs, including the association with persistent human papillomavirus (HPV) infection (Merino, 1991; Carter et al., 2001; Daling et al., 2002; zur Hausen, 2002; Hellman et al., 2004; Ferreira et al., 2008; Wu et al., 2008; Siriaunkgul et al., 2014) . HPV infection has been detected in 40% of vaginal cancers and HPV16 was the most HPV type detected (Daling et al., 2002; Hampl et al., 2006; Parkin et al., 2006; Srodon et al., 2006 neoplasia were suggested: one associated with infection by HPV, and a second independent of HPV infection (Del Pino et al., 2013; Siriaunkgul et al., 2014) .
During the last years, increasing interest has been focused on the role of p16
INK4A protein expression as a surrogate biomarker for cells expressing E7 oncogene in high-risk HPV-positive lesions of the uterine cervix (Keating et al., 2001; von Knebel Doeberitz et al., 2002; Bose et al., 2005; Benevolo et al., 2006; Kalof et al., 2006; Vinyuvat et al., 2008; Kurshumliu et al., 2009; Cheah et al., 2012; Genovés et al., 2014) . HPVs encode E6 and E7 oncoproteins, multifunctional immortalizing and growth-promoting proteins, that bind to and inactivate the tumor suppressor proteins p53 and the retinoblastoma family of tumor suppressor, respectively, leading to the overexpression of cyclin-dependent kinase inhibitor 16 (p16
INK4A
) as a means of genetic instability control (Rocco and Sidransky, 2001; Riethdorf et al., 2002; Lambert et al., 2006; O'Neill et al., 2006; Srivastava et al., 2013) .
Previously, we supported the role of p16
overexpression as a useful additional marker for the interpretation of problematic uterine cervix lesions reducing the variability during evaluation of suspicious biopsies (Missaoui et al., 2010b) . More anteriorly, we considered that p16 INK4A is a putative molecular biomarker that consistently discriminates uterine cervix adenocarcinomas from benign lesions and from endometrioid adenocarcinomas of the uterine corpus (Missaoui et al., 2006 INK4A alterations could be significant events in progression of vulvar disease (Chan et al., 1998) . More recently, Knopp et al. analyzed the p16 INK4A expression in larger series of vulvar SCCs and they reported a significant correlation between the high p16 INK4A expression and a better prognosis in the multivariate analysis and less risk of developing lymph node metastasis (Knopp et al., 2004 ).
In the current study, we analyzed the role of the p16 INK4A expression and the HPV infection in vaginal and vulvar SCCs cancers among Tunisian patients.
Materials and Methods

Tissue samples
We carried out a retrospective study of 30 female lower genital tract cancers retrieved from the surgical pathology files of the Department of Pathology, Farhet Hached University Hospital, Sousse, Tunisia. These cases were selected randomly. All slides were reviewed by two pathologists (Dr. Sihem Hmissa and Dr. Moncef Mokni). Ethical approval for use of all specimens was obtained from the research ethics committee of the Farhet Hached University Hospital.
The cases studied were distributed into the following groups, according to the World Health Organization (WHO) Classification of Tumors of the Breast and Female Genital Organs, 2003 (Wells et al., 2003) : 15 vulvar squamous cell carcinomas (SCCs) and 15 vaginal SCCs. All tissues had been routinely fixed in 4% buffered formalin and paraffin-embedded.
Immunohistochemistry for p
16INK4A protein expression The immunostaining procedure was carried out as we already described (Missaoui et al., 2006; Missaoui et al., 2010b; . Briefly, one or two paraffin blocks containing representative portions of the cancers were selected for each case and 4 μm-thick serial sections were obtained. Sections were incubated for 30 min with primary monoclonal antibodies against anti-p16
INK4A protein (Dako Cytomation, K5334, clone E6H4, dilution 1:50). The remaining part of the procedure was performed as we previously published (Missaoui et al., 2006; Missaoui et al., 2010b; . One invasive uterine cervix carcinoma with known diffuse and strong immunoreactivity with p16
INK4A
antibody was used as a positive control. Negative controls, using monoclonal mouse immunoglobulin G (IgG2a) antibody at a comparable concentration, were included.
Quantification of the p16
INK4A immunostaining In this study, we evaluated both nuclear and cytoplasmic p16 INK4A immunolabeling as previously described (McCluggage and Jenkins, 2003) . Briefly, a semi quantification of the immunostaining was carried out on both the staining intensity (0: no staining; 1: weak staining intensity; 2: intermediate; 3: strong staining intensity) and the percentage of positively stained tumor cells (0: no positive cells; 1: <5%, 2: 5-20%; 3: 21-50%; 4: 51-99%; 5: 100% positive tumor cells) by two independent pathologists (Sihem Hmissa and Moncef Mokni). After multiplication of both values, the immunostaining results were graded from 0 (no reactivity in tumor cells) to 15 (100% positive tumor cells with strong staining intensity).
In situ hybridization for HPV infection
The in situ hybridization technique was carried out as already described (Nabi et al., 2006; Hachana et al., 2010) . Briefly, one or two paraffin blocks containing representative portions of the cancers were selected for each case and 3μm-thick serial sections were obtained by microtome. A wide spectrum biotinylated probe for common HPV types was used according to the manufacturer's suggested protocol (Dako GenPoint K0620, Dako, Carpinteria, California, USA). The wide spectrum probe (Y1404) targets the genomic DNA of HPV types 6, 11, 16, 18, 30, 31, 33, 35, 45 , 51, and 52. Further HPV typing was carried out on cases found to be positive using the wide spectrum probe using specific probe for HPV16/18 (Y1412) according to manufacturer's protocol. Two uterine cervix cancer cases were used as positive control cases that were positive in previous reactions.
Statistical analysis
Data analyses were carried out using the Epi-Info 2002 software as previously described (Missaoui et al., 2006) . The association between p16
INK4A expression and HPV infection was analyzed by Chi-square statistics. Probability values of 0.05 or less were considered statistically significant. (Figure 1A-B Figure 1C) . However, strong and diffuse immunoreactivity for p16 INK4A (score 12 and 15) was observed in both the nucleus and cytoplasm in only 2 cases ( Figure 1D ). (Figure 2A) . Only 3 cancer cases were HPVnegative. The HPV16/18 infection was observed in 38.5% of vaginal SCCs HPV-positive (5 cases) ( Figure 2B) .
Results
Immunostaining
Among vulvar SCCs, HPV infection was detected in 40% of studied cases ( Figure 2C ). The remaining cases were HPV-negative by in situ hybridization (9 cases 
Discussion
During the last years, p16
INK4A expression has been considered as a surrogate marker for HPV-positive uterine cervix cancers (Benevolo et al., 2006; Vinyuvat et al., 2008; Kurshumliu et al., 2009; Missaoui et al., 2010b; Cheah et al., 2012; Genoves et al., 2014) . The role of p16 INK4A expression in the remaining female lower genital tract cancers is less studied. In this study, we extensively analyzed the immunohistochemical distribution of p16 INK4A protein expression in SCCs of the vagina and the vulva and the association with HPV infection. p16 INK4A expression was observed in the majority of vaginal SCCs with strong and diffuse p16
INK4A staining in 60% of cases. A significant association was observed between p16
INK4A positivity and HPV infection in vaginal SCCs. Our findings clearly support previous studies confirming the contribution of p16
INK4A expression and HPV infection in the carcinogenesis of vagina similar to that described in the uterine cervix cancers (Fuste et al., 2010; Alonso et al., 2012; Hellman et al., 2014) . In this regard, p16
INK4A staining is a useful marker for HPVpositive SCCs of the vagina. Fuste et al. (2010) analyzed the role of HPV and p16
INK4A protein in the pathogenesis of primary SCCs of the vagina. HPV was detected and typed by polymerase chain reaction (PCR) using SPF10 primers and p16 (Hellman et al., 2014) . Strong p16
INK4A expression was significantly correlated with low histopathological grade, HPV positivity, and long-term survival. Their findings indicated that p16I NK4A and Ki-67 expression might be useful in tumor grading and p16
INK4A expression could be used as a useful marker for HPV positivity in vaginal carcinoma (Hellman et al., 2014 (Riethdorf et al., 2004; der Avoort et al., 2006; Hoevenaars et al., 2008; de Sanjosé et al., 2013) .
Riethdorf et al. analyzed for p16 INK4A expression and HPV infection by RNA/RNA in situ hybridization in a large series of vulvar lesions (Riethdorf et al., 2004) . These researchers considered that, as in the uterine cervix, intense diffuse p16
INK4A expression supports an HPV-related neoplastic process in vulvar neoplasia, irrespective of the level of differentiation. However, the up-regulation of p16
INK4A at the epithelial-stromal interface in HPV-negative keratinizing SCCs is consistent with an HPV-independent response to alterations associated with invasion. In this regard, the disparate patterns of p16 Interestingly, van der Avoort et al. (2006) provided further evidence that vulvar SCCs is a multifactorial disease that develops from two different pathways. First, an HPV-dependent pathway with a remarkable resemblance to uterine cervix carcinomas and second, an HPV-independent pathway in which differentiated vulvar intraepithelial neoplasia III lesions that are high-risk HPVnegative, may be precursors.
Recently, a worldwide study of HPV infection in
